New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma

Single-arm, open-label, multicenter, phase II trial

Patients with uLMS, progression on ≥1 prior line treatment

Temozolomide +Olaparib (n=22

cORR: 27.0% [6 of 22 pts]

mPFS: 6.9 mos [5.4-NR], İTT population

mPFS:11.2 vs. 5.4 mos, HRD and HRP, respectively

Grade3: Neutropenia (65%), thrombocytopenia (32%), leukopenia (22%).

Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023